Solifenacin Succinate Versus Fesoterodine A Comparison Trial for Urgency Symptoms
Recruitment status was Recruiting
Objective 1: To advance the investigators understanding on the effect of solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD) on urinary urgency using a validated Urgency Severity and Impact Questionnaire (USIQ).
Hypothesis 1.1: The severity of urgency symptoms as measured by USIQ will change differently in women with OAB following a 3 month treatment with solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD).
Hypothesis 2.1: Condition-specific quality of life (QOL) as measured by USIQ will change differently in women with OAB following a 3 month treatment with solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD).
Objective 2: To advance the investigators understanding on the adverse events (AE's) of solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD).
Hypothesis 1.1: The severity and rate of AE's in women with OAB following a 3 month of treatment with solifenacin succinate (10 mg OD) vs. fesoterodine (8mg OD) will be different.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Solifenacin Succinate vs. Fesoterodine A Comparison Trial for the Treatment of Bothersome Urgency Symptoms|
- Changes in urgency sensation [ Time Frame: two months following treatment ] [ Designated as safety issue: No ]The effect of two different antochloinergic treatment on urgency symptoms will be measured by comparing USIQ scores changes in the two study arms, before and after treatment. Changes in urgency sensation will be analysed by subsiding the USIQ scopre at 2 months (second visit) from the USIQ score at baseline. Independent student t- test will be used for Comparison between the changes in USIQ score of the two groups.
- Adverse events [ Time Frame: two months ] [ Designated as safety issue: Yes ]Tolerability of both drugs will be monitored throughout the study based on reported AEs and discontinuations.
|Study Start Date:||May 2012|
|Estimated Study Completion Date:||May 2013|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
|Active Comparator: solifenacin succinate (10 mg OD)||
Drug: solifenacin succinate
8 mg once daily for 60 days
Other Name: vesicare
|Active Comparator: fesoterodine (8mg OD)||
8 mg, once daily for 60 dyas
Other Name: Toviaz
Please refer to this study by its ClinicalTrials.gov identifier: NCT01595152
|Contact: Lior Lowenstein, MD, MSemail@example.com|
|Rambam Health Care Campus||Recruiting|
|Contact: Lior Lowenstein, MD 048542382 firstname.lastname@example.org|
|Hadassah||Not yet recruiting|
|Contact: David Shveiky, MD 97248542653 email@example.com|
|Principal Investigator: David Shveiky, MD|
|Belinson||Not yet recruiting|
|Petach Tikva, Israel|
|Contact: Haim Krissi, MD 97248542653 firstname.lastname@example.org|
|Principal Investigator: Haim Krissi, MD|
|Asaf harofeh||Not yet recruiting|
|Tel Aviv, Israel|
|Contact: Anna Padoa, MD 97248542653 email@example.com|
|Principal Investigator: Anna Padoa, MD|
|Rebecca Ziv||Not yet recruiting|
|Contact: Naama Marcus, MD 97248542653 firstname.lastname@example.org|
|Principal Investigator: Naama Marcus, MD|
|Principal Investigator:||Anna Padoa, MD||Assaf-Harofeh Medical Center|
|Principal Investigator:||Haim Krissi, MD||Belinson Medical center|
|Principal Investigator:||David Shveiky, MD||Hadassa|
|Principal Investigator:||Naama Marcus, MD||Rebecca ziv|
|Principal Investigator:||Lior Lowenstein, MD, MS||Rambam Health Care Campus|